Industry: Biomedical Region: Finland Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
This is a Finnish company dedicated to developing in vitro models to imitate human biology, so as to achieve accurate, rapid and accessible drug development and research purposes.
Drugs and other types of medical treatment have different effects on traditional two-dimensional cell culture and animal and human biology. 90% of drugs verified in preclinical models or animals will fail during the transition to actual human clinical trials.
The company's technology provides a high-throughput, standardized organ-on-a-chip platform, which can be used for safety, effectiveness and toxicology tests in human models, thus significantly reducing the number of drugs that fail in the experimental stage, which is usually expensive. The company's platform links micro-technology with molecular biology to realize the development of physiological models and directly and reliably imitate human biology in the laboratory. The company has launched a platform that can simulate biological barriers with large throughput. Its technology provides faster, cheaper and more accurate research and development opportunities for the pharmaceutical industry and is helping the world discover new drugs.
The company currently focuses on preclinical CRO and drugs for early drug and treatment screening. However, this breakthrough technology has also attracted academic interest, because it provides key tools and new opportunities for researchers and biotechnologists to develop new forms of treatment.
Cooperation mode:
The company is currently looking for partners including China.